Haemonetics Corporation (HAE)
NYSE: HAEHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HAE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.47B
- P/E (TTM)
- 53.17
- Forward P/E
- 19.17
- EPS (TTM)
- $2.26
- Dividend yield
- None
- 52-week range
- 51.00 – 132.00
- Day range
- 119.68 – 122.00
- Volume / Avg
- 382.95K / 659.70K
- Beta
- —
- Shares outstanding
- 45.54M
52-week range
HAE stock today
Shares of Haemonetics (HAE) finished lower on Nov 20 at $120.16, a drop of 0.17% or $0.21 per share, versus the S&P 500's 3.70% decline. At this level, HAE sits near the top of its 52-week range of $51.00 to $132.00: 9.0% below the high, set on Nov 5, 2026 and 135.6% above the low. HAE is up 49.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.5%.
At 53.2x trailing earnings, Haemonetics trades in line with the peer-group median of 50.6x. Its forward P/E of 19.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Haemonetics
Company profileHaemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Christopher A. Simon
- Headquarters
- Boston, MA
- Employees
- 3,009
- IPO year
- 1991
- Website
- haemonetics.com
Financial highlights
Full financialsIn fiscal 2026, Haemonetics generated $1.33 billion in revenue, down 2.0% from fiscal 2025, its first annual decline since 2021. Net income was $97.3 million (-42.0% year over year), for a net margin of 7.3% versus a median of 9.1% in the prior 5 years. Gross margin was 59.0% (up from 55.0%) and operating margin 11.7%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.20M |
| Growth | -1.97% | +3.95% | +12.01% | +17.67% | +14.10% |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M |
| EPS (diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$147.18+22.49%
- Strong buy 4
- Buy 6
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $1.00 vs $1.30
- Surprise
- -23.08%
HAE news
All HAE news- Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure SystemPR Newswire
- Haemonetics (HAE) Q2 2027 Earnings Call TranscriptNasdaq
- Haemonetics outlines FY 2027 organic growth of 6%-9% while scaling CSL Persona PLUS rollout through calendar 2027Seeking Alpha
- Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run?NasdaqHAE, GEHC
- Haemonetics Corporation Reports Second Quarter Fiscal 2027 Revenue of $357.8 millionNasdaq
- Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations WebsitePR Newswire
- Haemonetics Q2 2027 Earnings PreviewSeeking Alpha
- GEHC vs. HAE: Which Stock Is the Better Value Option?NasdaqGEHC, HAE
Haemonetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MMSIMerit Medical Systems Inc. | 84.34 | -0.08% | $5.05B | vs HAE |
| TFXTeleflex Incorporated | 161.58 | -1.11% | $6.41B | vs HAE |
| MMEDMiniMed Group Inc. | 16.01 | -1.54% | $4.50B | vs HAE |
| ICUIICU Medical Inc. | 172.52 | -1.84% | $4.31B | vs HAE |
| STVNStevanato Group S.p.A. | 15.65 | -1.76% | $4.27B | vs HAE |
| HTFLHeartflow Inc. | 46.69 | +4.62% | $4.10B | vs HAE |
| NVSTEnvista Holdings Corporation | 22.91 | -1.55% | $3.67B | vs HAE |
| PLSEPulse Biosciences Inc | 45.55 | +2.57% | $3.35B | vs HAE |
Indexes, lists and sector
Haemonetics stock FAQ
What is Haemonetics's stock price today?
HAE last traded at $120.16 as of Nov 20, 4:00 PM EST, down 0.17% on the day. Prices are delayed at least 15 minutes.
Does Haemonetics pay a dividend?
No. Haemonetics does not currently pay a regular cash dividend.
What is HAE's P/E ratio?
HAE trades at a trailing P/E ratio of 53.17 and a forward P/E of 19.17, compared with a median of 50.6 for its closest peers.
Who is Haemonetics's CEO?
Mr. Christopher A. Simon is the chief executive officer of Haemonetics Corporation, which has about 3,009 employees.
Has HAE ever split its stock?
Yes. The most recent HAE stock split was a 2-for-1 split on Dec 3, 2012, one of 2 splits on record.
What is the HAE 52-week high?
The 52-week high for HAE is $132.00 and the 52-week low is $51.00. The stock is currently 9.0% below its high.